B-lymphocyte antigen CD19 (CD19) (CD19)

B-lymphocyte antigen CD19 (CD19) is a 95 kDa type I transmembrane glycoprotein and a member of the immunoglobulin superfamily (UniProt P15391). It is expressed exclusively on the surface of B-lineage cells, from the early pro-B cell stage through terminal differentiation into plasma cells, making it a highly specific marker for B-cells (Wang et al., 2012). Biologically, CD19 functions as a critical signaling component of the B-cell receptor (BCR) complex, where it acts as a co-receptor that lowers the threshold for antigen-dependent B-cell activation and recruits signaling molecules like phosphatidylinositol 3-kinase (PI3K) (Carter & Fearon, 1992). In the context of disease, CD19 is frequently overexpressed in various B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphomas (NHL) (Tedder, 2009). This restricted expression pattern and high prevalence in cancers have made CD19 a primary target for innovative immunotherapies, such as chimeric antigen receptor (CAR) T-cells (e.g., Tisagenlecleucel), CAR-NK cells (e.g., NEUK203-215), and bispecific T-cell engagers (e.g., Blinatumomab) (FDA Label Kymriah; Neelapu et al., 2018). While highly effective, targeting CD19 can result in on-target, off-tumor toxicities, most notably B-cell aplasia and subsequent hypogammaglobulinemia, as well as systemic inflammatory responses like cytokine release syndrome (CRS) (Neelapu et al., 2018).

Other names

B-lymphocyte surface antigen B4T-cell surface antigen Leu-12CVID3B4

CD19-targeted therapies operate through several mechanisms: CAR-T and CAR-NK cells (like NEUK203-215) utilize a chimeric antigen receptor to recognize CD19 and trigger direct cytotoxic killing of B-cells (Neelapu et al., 2018); bispecific T-cell engagers (BiTEs) like blinatumomab bridge CD3-positive T-cells to CD19-positive B-cells to induce lysis (FDA Label Blincyto); antibody-drug conjugates (ADCs) like loncastuximab tesirine deliver cytotoxic payloads directly into CD19-expressing cells via internalization (Wang et al., 2012); and monoclonal antibodies like tafasitamab enhance antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) (Tedder, 2009).